about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersMyelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Biology of the bone marrow microenvironment and myelodysplastic syndromes.Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromesThe clonal origins of leukemic progression of myelodysplasia.Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Time-dependent changes in mortality and transformation risk in MDS.Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes.Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
P2860
Q26743743-9F11BE26-9EDC-4295-88ED-7FB3F663F671Q28387115-338CDA1D-31B0-4A77-A087-64E5F7186DCDQ30353404-2F72102D-BD3B-4D29-A098-4A160252BF43Q36201068-9875154E-4DFB-4B1E-ABEA-AA5B396DB80CQ37685237-C3ACFA3A-C201-4DCC-AE8C-35E1303D3655Q38406756-741912D9-F7DB-4A84-9E65-ADAD7BA0A0C2Q38905610-952DBD4F-80C5-4394-9906-B1BD25ABD5BFQ39661429-DAF9C738-337C-4698-A9AC-62A9CE721FE0Q39970255-71A8DA0F-0070-4C80-942C-4A6ACBBB9617Q40437221-A1BBCDC5-D1B0-4B20-8267-75B5CB3D84E5Q40793299-6B5BF8C6-DDAF-48A7-8CA6-D596EB3A3254Q42693220-83CE4C12-01CF-4433-829F-2DC83AF0F963Q48137636-4D67BA26-EF6F-4BBE-8652-5DA2E1AA89A8Q49021366-5D8A6286-FBE6-4689-BA8A-29D65F3CD6D5Q49391428-4B84D45D-AF9D-4E18-9299-E24B69852A64
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Myelodysplastic syndromes, version 2.2015
@ast
Myelodysplastic syndromes, version 2.2015
@en
type
label
Myelodysplastic syndromes, version 2.2015
@ast
Myelodysplastic syndromes, version 2.2015
@en
prefLabel
Myelodysplastic syndromes, version 2.2015
@ast
Myelodysplastic syndromes, version 2.2015
@en
P2093
P2860
P356
P1476
Myelodysplastic syndromes, version 2.2015
@en
P2093
Amir T Fathi
Amy E DeZern
Bart Scott
Benton Wheeler
Brady L Stein
Carlos M De Castro
Courtney Smith
Daniel A Pollyea
David Head
Dorothy A Shead
P2860
P304
P356
10.6004/JNCCN.2015.0038
P577
2015-03-01T00:00:00Z